Ms. Varshita Srivastava is a molecular parasitology researcher specializing in antimalarial drug discovery, virtual screening, molecular cloning, biochemical characterization, and Plasmodium falciparum parasite biology. Her research integrates in silico therapeutic prediction with experimental validation to identify novel strategies for overcoming drug resistance in malaria. She has extensive experience in molecular docking, high-throughput virtual screening, molecular dynamics simulations, and structural modeling, along with strong laboratory skills in recombinant protein expression, purification, enzyme assays, SDS-PAGE, Western blotting, and troubleshooting of protein solubilization challenges. In parasitology, she routinely handles P. falciparum culture under biosafety conditions, performs drug sensitivity assays, IC₅₀ calculations, parasite synchronization, microscopy-based stage identification, and phenotypic assessments to evaluate the efficacy of candidate molecules. Her work spans multi-target drug discovery, immunotherapeutic design, peptide–ligand conjugates, and identification of FDA-approved repurposed drugs, contributing to research on malaria, dengue, monkeypox, and SARS-CoV-2. She has co-authored impactful publications in high-quality journals, including studies on kinase inhibition, proteogenomic annotation, natural product screening, antiviral peptide inhibitors, and immunotherapy models. Beyond malaria, her interdisciplinary research extends to computational immunology, antiviral therapeutics, systems biology, and high-throughput data analyses. She has contributed book chapters on marine anti-viral compounds, microRNA applications, and systems biology approaches, reflecting her broad scientific engagement. Her growing scientific impact is reflected in 75 citations across 59 documents, supported by 10 peer-reviewed publications and an h-index of 5, underscoring the visibility and influence of her research contributions. Recognized for her academic excellence and research achievements, she has received multiple national-level awards for oral and poster presentations and has participated in international scientific conferences and advanced training programs. Her work reflects a complete bench-to-computer pipeline aimed at developing innovative therapeutic solutions for parasitic and viral diseases.